Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.92−0.08 (-2.00%)
Close on Nov 13, 2026Market cap $577.02MP/E –Yield –
Aclaris Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Aclaris Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$90.10M. For fiscal 2025 it was -$75.92M. The highest annual figure on record is -$20.58M in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$75.92M | – |
| FY2024 | Dec 31, 2024 | -$141.13M | – |
| FY2023 | Dec 31, 2023 | -$96.49M | – |
| FY2022 | Dec 31, 2022 | -$89.06M | – |
| FY2021 | Dec 31, 2021 | -$88.80M | – |
| FY2020 | Dec 31, 2020 | -$49.59M | – |
| FY2019 | Dec 31, 2019 | -$104.65M | – |
| FY2018 | Dec 31, 2018 | -$82.90M | – |
| FY2017 | Dec 31, 2017 | -$53.96M | – |
| FY2016 | Dec 31, 2016 | -$48.45M | – |
| FY2015 | Dec 31, 2015 | -$20.58M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$21.24M | – |
| Q2 FY2026 | Jun 30, 2026 | -$24.13M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.09M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.04M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.29M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.96M | – |
| Q4 FY2024 | Dec 31, 2024 | -$99.53M | – |
| Q3 FY2024 | Sep 30, 2024 | -$10.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.61M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.69M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$31.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.72M | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.68M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$18.70M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.10M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.76M | – |
| Q1 FY2021 | Mar 31, 2021 | -$28.24M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.01M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.87M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.78M | – |
| Q1 FY2020 | Mar 31, 2020 | -$14.93M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.23M | – |
| Q3 FY2019 | Sep 30, 2019 | -$21.23M | – |
| Q2 FY2019 | Jun 30, 2019 | -$41.37M | – |
| Q1 FY2019 | Mar 31, 2019 | -$24.83M | – |
| Q4 FY2018 | Dec 31, 2018 | -$23.09M | – |
| Q3 FY2018 | Sep 30, 2018 | -$20.96M | – |
| Q2 FY2018 | Jun 30, 2018 | -$31.66M | – |
| Q1 FY2018 | Mar 31, 2018 | -$30.73M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.20M | – |
| Q3 FY2017 | Sep 30, 2017 | -$18.64M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.24M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.88M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.59M | – |
See a number that looks wrong?